Jones Tiffanie K, Reilly John P, Anderson Brian J, Miano Todd A, Karanam Brijesh, Ittner Caroline A G, Shashaty Michael G S, Feng Rui, Meyer Nuala J
Pulmonary, Allergy, and Critical Care Medicine Division, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Division of Biostatistics, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
Crit Care Explor. 2025 Aug 12;7(8):e1294. doi: 10.1097/CCE.0000000000001294. eCollection 2025 Aug 1.
The vascular endothelial growth factor (VEGF) signaling pathway is important in the pathogenesis of acute respiratory distress syndrome (ARDS) with supportive genetic and proteomic evidence. Genetic polymorphisms within FLT1, which encodes VEGF receptor 1, associate with risk of ARDS in sepsis. Soluble Fms-like tyrosine kinase-1 (sFlt-1) is a secreted splice variant of FLT1 that acts as a potent antagonist to circulating VEGF.
To assess the association between early plasma concentrations of sFlt-1 and risk of ARDS and to determine if ARDS mediates the relationship between sFlt-1 and mortality during sepsis.
DESIGN, SETTING, AND PARTICIPANTS: In a prospective cohort study, we enrolled 198 critically ill patients with sepsis per Sepsis-2 criteria. ARDS was defined per Berlin criteria.
Levels of sFlt-1 were quantified using electrochemiluminescence on plasma collected in the emergency department upon admission. We tested the association between plasma levels of sFlt-1 with ARDS and mortality using logistic regression adjusting for age, sex, and pulmonary versus nonpulmonary source of sepsis. We applied causal mediation analysis to determine the percentage of the total effect of sFlt-1 on mortality that was mediated by ARDS.
We enrolled 198 patients; ARDS developed within 6 days in 29%. Plasma levels of sFlt-1 were significantly associated with risk of ARDS in sepsis (odds ratio [OR], 1.91 per log increase; 95% CI, 1.31-2.76 per log increase; p < 0.01). Plasma sFlt-1 levels were also associated with mortality (OR, 2.19 per log increase; 95% CI, 1.57-3.08 per log increase; p < 0.01). ARDS mediated 20.3% (95% CI, 6.9-98.1%) of the total effect of sFlt-1 on mortality (p < 0.01).
Higher plasma levels of sFlt-1 were associated with an increased risk of ARDS and ARDS mediated a significant proportion of the sFlt-1-associated mortality observed during sepsis. Our findings further implicate dysregulated VEGF signaling in ARDS and suggest that plasma sFlt-1 merits further investigation as an early endothelial therapeutic target for sepsis-associated ARDS and mortality.
血管内皮生长因子(VEGF)信号通路在急性呼吸窘迫综合征(ARDS)的发病机制中起重要作用,有支持性的遗传学和蛋白质组学证据。编码VEGF受体1的FLT1基因多态性与脓毒症中ARDS的风险相关。可溶性Fms样酪氨酸激酶-1(sFlt-1)是FLT1的一种分泌性剪接变体,可作为循环VEGF的有效拮抗剂。
评估早期血浆sFlt-1浓度与ARDS风险之间的关联,并确定ARDS是否介导sFlt-1与脓毒症期间死亡率之间的关系。
设计、地点和参与者:在一项前瞻性队列研究中,我们根据脓毒症-2标准纳入了198例脓毒症重症患者。ARDS根据柏林标准定义。
使用电化学发光法对急诊科入院时采集的血浆中的sFlt-1水平进行定量。我们使用逻辑回归分析,对年龄、性别以及脓毒症的肺部与非肺部来源进行校正,测试血浆sFlt-1水平与ARDS和死亡率之间的关联。我们应用因果中介分析来确定sFlt-1对死亡率的总效应中由ARDS介导的百分比。
我们纳入了198例患者;29%的患者在6天内发生ARDS。脓毒症中血浆sFlt-1水平与ARDS风险显著相关(比值比[OR],每对数增加1.91;95%可信区间[CI],每对数增加1.31 - 2.76;p < 0.01)。血浆sFlt-1水平也与死亡率相关(OR,每对数增加2.19;95% CI,每对数增加1.57 - 3.08;p < 0.01)。ARDS介导了sFlt-1对死亡率总效应的20.3%(95% CI,6.9 - 98.1%)(p < 0.01)。
较高的血浆sFlt-1水平与ARDS风险增加相关,且ARDS介导了脓毒症期间观察到的sFlt-1相关死亡率的很大一部分。我们的研究结果进一步表明VEGF信号通路失调与ARDS有关,并提示血浆sFlt-1作为脓毒症相关ARDS和死亡率的早期内皮治疗靶点值得进一步研究。